Prognosis
Novavax’s Shot Effective Against Covid in Final Trial Analysis
This article is for subscribers only.
Novavax Inc.’s Covid-19 vaccine was 96.4% effective against mild, moderate and severe symptoms of the disease in the final analysis of a late-stage trial in the U.K.
Shares of the drugmaker were up 16% in after-hours trading Thursday in New York. Since the start of this year, the stock had gained more than 68% through Thursday’s close.